-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Shattuck Labs Announces Participation in Upcoming September Conferences
Shattuck Labs Announces Participation in Upcoming September Conferences
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in September 2022.
Presentation Details
Conference: Citi's 17th Annual BioPharma Conference
Format: Targeted Oncology panel discussion with covering analyst Yigal Nochomovitz
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: September 8, 2022
Time: 2:40 p.m. ET
Conference: H.C. Wainwright 24th Annual Global Investment Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: September 12, 2022
Time: 7:00 a.m. ET
A live webcast of the presentations will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in September 2022.
德克萨斯州奥斯汀和北卡罗来纳州达勒姆,9月2022年01日(环球通讯社)-沙塔克实验室公司(纳斯达克:STTK)是一家临床阶段的生物技术公司,率先开发双功能融合蛋白作为治疗癌症和自身免疫性疾病患者的新型生物药物。该公司今天宣布,公司管理层将参加2022年9月举行的两次投资者大会。
Presentation Details
演示详细信息
Conference: Citi's 17th Annual BioPharma Conference
Format: Targeted Oncology panel discussion with covering analyst Yigal Nochomovitz
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: September 8, 2022
Time: 2:40 p.m. ET
会议:花旗第17届生物制药年会
格式:与采访分析师Yigal Nochomovitz进行目标肿瘤学小组讨论
推荐人:Taylor Schreiber,医学博士,Shattuck首席执行官
日期:2022年9月8日
时间:下午2:40外星人
Conference: H.C. Wainwright 24th Annual Global Investment Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: September 12, 2022
Time: 7:00 a.m. ET
会议:H.C.Wainwright第24届全球投资年会
格式:企业演示文稿
推荐人:Taylor Schreiber,医学博士,Shattuck首席执行官
日期:2022年9月12日
时间:上午7:00外星人
A live webcast of the presentations will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.
演示文稿的现场网络直播将在公司网站的活动和演示部分进行。网络直播的重播将在演示日期后存档最多90天。
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
Shattuck Labs,Inc.简介
沙塔克实验室公司(纳斯达克代码:STTK)是一家临床阶段的生物技术公司,致力于将双功能融合蛋白作为一种新型生物药物开发出来,用于治疗癌症和自身免疫性疾病。来自Shattuck专有的激动剂重定向检查点的化合物,Arc®,平台同时抑制检查点分子和激活共刺激分子与单一的治疗。该公司的SL-172154(Sirpα-FC-CD40L)计划旨在阻断CD47免疫检查点,同时激活CD40途径,正在进行多个阶段的试验评估。第二种候选产品SL-279252(PD1-FC-OX40L)正在实体瘤或淋巴瘤的第一阶段试验中进行评估。此外,该公司正在推进一种专有的伽玛三角洲T细胞接入器GADLEN™平台,该平台旨在将伽玛三角洲T细胞与肿瘤抗原连接起来,用于癌症患者的治疗。Shattuck在德克萨斯州的奥斯汀和北卡罗来纳州的达勒姆都有办事处。有关更多信息,请访问:。
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
投资者联系方式:
康纳·理查森
董事高级金融与投资者关系部
Shattuck实验室,Inc.
邮箱:InvestorRelationship@shattucklab
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧